Catalyst Pharmaceuticals. $3.1B market cap. 25 analysts. Rare disease pharma with one good product, one great product, one dying product, and a trial in 25 days that determines whether 61% of revenue survives.

At first glance this looks interesting. $589M revenue growing 20%, $214M net income, $709M cash (23% of market cap), forward P/E 9.5x, and what yfinance flagged as "$2.5M in insider buying" ahead of the March 23 Hetero patent trial. We pulled the 10-K. Then we pulled the Form 4s.

The insider buying doesn't exist.

What the Form 4s Actually Show

Seven filings, Nov 2025 through Feb 2026. Every single "acquisition" is Code M — RSU vests or option exercises. Zero Code P open market purchases. Not one insider voluntarily bought a single share ahead of the most important trial in company history.

It gets worse:

  • Molly Harper (Director): Exercised 20,000 options at $5.78, then sold 26,746 shares at $23.06-23.73. Liquidated 92% of her holdings. She didn't just take profits on the exercise — she dumped her existing position too.
  • Jeffrey Del Carmen (Chief Commercial Officer): Exercised 10,983 options at $4.21, sold everything at $23.33 same day. 100% disposal of exercised shares. The CCO — the person responsible for selling FIRDAPSE — sold his stock.
  • Patrick McEnany (Chairman): Gifted 135,000 shares across three transactions. Estate planning, sure. But he's reducing direct ownership from 4.33M to 4.15M shares, not loading up.
  • Everyone else: Routine RSU vests with automatic tax withholding. Passive retention, not conviction.

This is the dog that didn't bark. If management believed Hetero was a layup — if the 70% win probability the settlement pattern implies were a confident internal view — someone would have bought. Options are cheap. Stock is $25. $709M in cash on the balance sheet. Nobody bought.

The Trial

Hetero is the last remaining Paragraph IV challenger to FIRDAPSE. Teva settled Jan 2025, Lupin settled Aug 2025 — both agreed to no generic entry before Feb 25, 2035. The settlement pattern is bullish: 2 of 3 challengers capitulated pre-trial, consistent with HRMY's pattern where 5 of 6 settled after claim construction.

But Hetero refused to settle when it could have taken the same deal. That's either a small generic taking a shot with nothing to lose (likely) or a company that found a real hole in the patents (possible). FIRDAPSE patents expire 2032-2037; orphan exclusivity already expired Nov 2025. If Hetero wins AND gets FDA ANDA approval, generic amifampridine hits mid-2026. That's $358M in revenue — 61% of the company — at existential risk.

Our estimate: 70% CPRX wins. The market's estimate (derived from options and price): 60-70%. No gap.

The Numbers That Don't Work

Factor regression: 64.7% idiosyncratic variance, below the 75% threshold. XBI beta 0.64 (29.4% of variance). Regression alpha: -7.6% annual. This stock moves with biotech, not with its own thesis.

Forward alpha calculation:

Win scenario (70%):  $33-35 target  → +35% from $25
Loss scenario (30%): $14-18 target  → -36% from $25
Probability-weighted: $28.70         → +14% raw

Minus risk-free (5%): +9%
Minus sector (8%):    +5.9% idio return
Edge%:                0% (no informational advantage)
α = 0.0%

25 analysts cover this name. We have no edge on the trial outcome (we can't evaluate Hatch-Waxman patent claims), no edge on AGAMREE commercialization (consensus already models $150M+), and no edge on capital allocation ($709M sitting idle with "no definitive agreements" on BD).

What IS Good

AGAMREE (vamorolone for DMD) is genuinely impressive: $117M in its first full year, international expansion ramping (UK NICE, German reimbursement, Swiss approval, Japan launch), orphan protection through April 2031, additional indication milestones worth $140M. This is a real growth engine that could eventually decouple from FIRDAPSE dependency.

NCCN updated SCLC guidelines to include LEMS screening (Aug 2025), expanding the FIRDAPSE patient funnel through oncology. Long-term structural, but only matters if FIRDAPSE survives Hetero.

The cash position ($709M, earning $25M/year in interest) provides a meaningful floor — roughly $5.80/share in cash alone. The bear case isn't zero.

Verdict

Good company. No alpha. Market is pricing the Hetero binary approximately correctly at 60-70% win. Insiders aren't buying — they're selling and gifting. Factor decomposition shows this is a biotech sector bet masquerading as a stock pick. Forward α = 0%.

The one thing worth tracking: AGAMREE's trajectory. If it hits $200M+ in 2026 AND FIRDAPSE survives Hetero, this re-rates materially. But that's a consensus view with no edge, and "buy a good company at fair value" isn't a thesis.

Pass.